● neutral
Impact
PhaseApproved
Time to marketAlready on the market — approved since 2008 (IR) and 2011 (ER)
Nucynta ER tapentadol hydrochloride Updated Oct 24
What to watch
Nucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.
Bull case
- Nucynta ER is a well-established branded opioid with a differentiated dual-mechanism profile (mu-opioid agonist + norepinephrine reuptake inhibition) that still generates meaningful revenue
- Collegium's analyst consensus is heavily bullish, 12 buy/strong buy vs 2 hold vs 0 sell, with a mean price target of ~$49 (113% upside from ~$23)
- COLL trades significantly below its 52-week high ($50.79) and 200-day SMA ($33.83), presenting a potential value entry if the portfolio transition to ADHD succeeds
Bear case
- Nucynta ER faces ongoing generic competition from Hikma Pharmaceuticals and other manufacturers, driving revenue erosion as a mature opioid product
- COLL stock is down ~55% from its 52-week high of $50.79, trading at $22.96 with a neutral technical score (-11), well below its 200-day SMA
- The company took on significant debt to acquire AZSTARYS for $650M, integration risk and debt service could pressure financials